尼拉帕利与他汀类药物在卵巢癌临床试验中的潜在协同效应。
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.
作者信息
Zhang Hailei, Rutkowska Anna, González-Martín Antonio, Mirza Mansoor R, Monk Bradley J, Vergote Ignace, Pothuri Bhavana, Graybill Whitney A Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Feng Bin
机构信息
Precision Medicine, R&D, GSK, Waltham, Massachusetts.
Cellzome, a GSK Company, R&D, GSK, Heidelberg, Germany.
出版信息
Cancer Res Commun. 2025 Jan 1;5(1):178-186. doi: 10.1158/2767-9764.CRC-24-0191.
The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.
据我们所知，此次呈现的回顾性分析首次表明，在临床环境中，他汀类药物与尼拉帕利之间可能存在显著的相互作用。然而，需要进一步研究以更好地了解其潜在的临床益处。
Zotero 插件